Compare GASS & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GASS | LCTX |
|---|---|---|
| Founded | 2004 | 1990 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 345.6M | 407.7M |
| IPO Year | 2005 | 1996 |
| Metric | GASS | LCTX |
|---|---|---|
| Price | $9.11 | $1.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 242.8K | ★ 1.1M |
| Earning Date | 03-02-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,556,000.00 |
| Revenue This Year | N/A | $55.75 |
| Revenue Next Year | N/A | $2.96 |
| P/E Ratio | $5.00 | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $4.90 | $0.37 |
| 52 Week High | $10.52 | $2.09 |
| Indicator | GASS | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.03 | 32.08 |
| Support Level | $8.67 | $0.94 |
| Resistance Level | $10.52 | $1.84 |
| Average True Range (ATR) | 0.46 | 0.11 |
| MACD | -0.08 | -0.04 |
| Stochastic Oscillator | 29.19 | 1.85 |
StealthGas Inc is an international shipping transportation company. It owns liquefied petroleum gas (LPG) pressurized carriers and provides international seaborne transportation services to LPG producers and users, as well as crude oil and product carriers to oil producers, refineries, and commodities traders. The company carriers carry various petroleum gas products in liquefied forms, such as propane, butane, butadiene, isopropane, propylene, and vinyl chloride monomer, which are all byproducts of the production of crude oil and natural gas.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.